TY - JOUR
T1 - Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
AU - Nastoupil, Loretta J.
AU - Bartlett, Nancy L.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
AB - Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85147094560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147094560&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.01848
DO - 10.1200/JCO.22.01848
M3 - Review article
C2 - 36508700
AN - SCOPUS:85147094560
SN - 0732-183X
VL - 41
SP - 903
EP - 913
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 4
ER -